

### Remarks

Upon entry of the above amendments this application will contain claims 1, 7, 10-12, 14, 15, 20-22, 36-42 pending. Claims 1, 7, 10-12, 14, 15, 36, and 37 were considered to allowable. Claims 20-22 were rejected. New claims 38-42 have been added. As discussed more fully below, it is believed that all the claims are now in condition for allowance. Therefore, reconsideration leading to withdrawal of all rejections is requested.

#### I. Rejections under 35 USC §112, First and Second Paragraph

Claims 20-22 were rejected under 35 USC §112, first and second paragraph as failing to comply with the enablement requirement for the prevention of the diseases recited in claims 20-22. While it is maintained that written specification is sufficient to comply with the written description requirement, in order to advance this application to allowance, claim 20 has been amended to recite to a “method of treating mammal to alleviate the pathological effects of osteoporosis or psoriasis”. It is believed that this amendment places this application in condition for allowance. Therefore, withdrawal of this rejection is requested.

#### II. New Claims

New claims 38-42 have been added and each depend either directly or indirectly from allowed claim 11. New claims 38-42 each recite the subject matter of claims 14, 15, and 20-22 (as amended) respectively. Consequently, it is believed that these new claims do not add any new matter. Entry of these claims is requested.

#### III. Conclusion

In light of the above amendments and comments withdrawal of all rejections and timely reconsideration leading to allowance of all pending claims are respectfully requested. The Examiner is invited to contact the undersigned attorney by telephone if there are any questions about this Submission or other issues that may be resolved in that fashion.

Respectfully submitted,

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana  
46206-6288

/James B. Myers/  
James B. Myers  
Attorney for Applicants  
Registration No. 42,021  
Phone: 317-276-0755